Table 2.

Examples of ongoing sipuleucel-T combination studies

Trial	National clinical trial identifier	Statusa
Concurrent vs. sequential sipuleucel-T and abiraterone	NCT01487863	Randomized phase II, Reported in 2015 [44]
Sipuleucel-T +/- RT	NCT01807065	Randomized Phase II, Recruiting, Expected completion date June 2017
Sipuleucel-T +/- pTVG-HP DNA booster vaccine	NCT01706458	Randomized pilot study, Recruiting, Expected completion date December 2016
Sipuleucel-T + indoximod	NCT01560923	Randomized phase II Recruiting, Expected completion date December 2016
Sipuleucel-T +/- ipilimumab	NCT01804465	Randomized phase II, Recruiting, Expected completion date December 2017
Sipuleucel-T +/- radium - 223	NCT02463799	Randomized phase II, Recruiting, Expected completion date December 2018

^a As determined by ClinicalTrials.gov accessed October 31, 2016